Studies have shown that FOXA2 could function as a tumor suppressor by selectively binding to the promoter of several genes related to epithelial–mesenchymal transition (EMT), such as Slug, CDH1 or Zeb2, to suppress tumor migration and progression in lung cancer, breast cancer or liver cancer (15, 16, 17). This evidence concerns the gene FOXA2 and breast cancer.